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Introduction
The TNF family has an important role in inducing var-
ious biological responses such as cell proliferation, dif-
ferentiation, survival, and death (1). Two recently
described cytokines, APRIL and BLyS (also called BAFF,
THANK, TALL-1, and zTNF4), form a new subfamily of
TNF-like ligands (2–7). BLyS and APRIL are synthesized
as type II transmembrane proteins and proteolytically
cleaved at a multibasic motif (4, 8, 9). APRIL is
processed intracellularly by furin convertase prior to its
secretion, thus acting solely as a secreted factor, where-
as BLyS is released from the cell surface by processing of
membrane-bound BLyS (4, 8, 9). Two members of the
TNF receptor family, the transmembrane activator and
calcium modulator cyclophilin ligand interactor (TACI)
and B cell maturation antigen (BCMA), have been iden-
tified as receptors that can bind both APRIL and BLyS
with comparable efficacy (7, 10–13). More recently, a
third receptor was identified that is unique to BLyS
(BAFF-R or BR3); this receptor further enhances the
complexity of this subfamily (14, 15). Expression of
BCMA, TACI, and BR3 is observed on B cells, whereas
TACI is also expressed on activated T cells (16).
A clue to the role of this receptor/ligand subfamily in
immunity came from the observation that treatment of
mice with a soluble decoy form of TACI or BCMA
(TACI-Fc or BCMA-Fc) led to reduced B cell numbers
and a block in the humoral response (10, 12, 13, 17, 18).
These effects have been attributed to BLyS sequestra-
tion, as (a) BLyS acts as a costimulator of B cells in the
presence of anti-IgM antibodies (3–5); (b) in vivo admin-
istration of a soluble form of BLyS disrupts spleen
architecture due to increased B cell numbers (3); (c) mice
that express BLyS as a transgene have enlarged spleens
and lymph nodes and display autoimmunity due to B
cell expansion as a result of increased survival of nor-
mally deleted B cells (6, 7, 19); and (d) BLyS-deficient
mice have a phenotype comparable to that of TACI-Fc–
or BCMA-Fc–treated mice, i.e., almost complete loss of
mature B cells and a severely decreased humoral
response (20, 21). This last observation in particular
suggests that BlyS binding to TACI and/or BCMA is
essential for B cell survival and function. Paradoxically,
TACI-deficient mice show B cell expansion rather than
death, whereas BCMA knockout mice have no overt
phenotype (20, 22–24). This points to an unexpected
role for TACI in negative regulation of B cell growth and
a possibly redundant role for BCMA. Despite the B cell
expansion, in at least one report the T cell–dependent
humoral response appeared normal in the TACI knock-
out mice (22). A significant decrease is observed, how-
ever, in responses to T cell–independent type 2 (TI-2)
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munity, but the biological role of APRIL remains less well defined. Analysis of T cells revealed an acti-
vation-dependent increase in APRIL mRNA expression. We therefore generated mice expressing
APRIL as a transgene in T cells. These mice appeared normal and showed no signs of B cell hyper-
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staphylococcal enterotoxin B–reactive CD4+ T cells in vivo, which both directly correlate with elevat-
ed Bcl-2 levels. Analysis of humoral responses to T cell–dependent antigens in the transgenic mice
indicated that APRIL affects only IgM but not IgG responses. In contrast, T cell–independent type 2
(TI-2) humoral response was enhanced in APRIL transgenic mice. As TACI was previously reported
to be indispensable for TI-2 antibody formation, these results suggest a role for APRIL/TACI inter-
actions in the generation of this response. Taken together, our data indicate that APRIL is involved
in the induction and/or maintenance of T and B cell responses.
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antigens (22, 23). These apparently contradictory find-
ings in BLyS, TACI, and BCMA knockout mice were at
least partly clarified with the identification of BR3, the
third receptor for BLyS. This receptor appears to medi-
ate most of the B cell survival signal elicited by BLyS and
explains to a large extent the phenotype of the BLyS
transgenic (Tg) animals.
In addition to a defect in B cell immunity, BLyS Tg
mice have increased numbers of activated CD4+ and
CD8+ T cells (7, 19). Although these effects have not
been characterized to the same extent as have the
changes in B cell homeostasis, they do point to a pos-
sible role for BLyS in T cell activation. In agreement,
BLyS was recently reported to provide costimulation
for suboptimally activated T cells (17).
The role of APRIL in immune regulation is less well
defined. APRIL was originally described to stimulate
growth of tumor cells in vitro and in vivo (2). Recently,
reports described the potential of recombinant APRIL
to act as a costimulator of primary B and T cells in vitro
and to stimulate IgM production by peripheral blood
B cells in vitro (18, 25). Similar to BLyS, in vivo appli-
cation of APRIL results in splenomegaly due to expan-
sion of the B cell population and an increase in the per-
centage of activated T cells (18), suggesting a role for
APRIL in lymphoid homeostasis as well. To better char-
acterize this function, we generated APRIL Tg mice and
have determined the role of APRIL in lymphoid devel-
opment and activation.
Methods
Generation and screening of lck-APRIL Tg mice. The human
APRIL cDNA coding region was inserted into a target-
ing vector containing the lck distal promoter fused to
human growth hormone (hGH) intronic and
polyadenylation sequences (26). The resulting con-
struct was injected into BALB/c × C57BL/6 embryos,
and Tg founders and offspring were screened by PCR
of tail DNA using oligonucleotide forward primer H19
5′-ATGGATTACAAAGACGATGACG-3′ and reverse primer
H14 5′-TCACAGTTTCACA AACCCCAGG-3′. The APRIL
Tg mice were backcrossed on a C57BL/6 background.
Mice used in experiments had been backcrossed at least
five times onto the C57BL/6 background.
RT-PCR. Naive CD4+ T cells were isolated from the T
cell receptor (TCR) Tg DO11.10 mice as described (27).
Isolated T cells were restimulated (in the absence of
irradiated splenocytes) with 5 mM of the relevant oval-
bumin (OVA) peptide and in the presence of IL-12 and
anti–IL-4 to generate Th1 cells, or in the presence of
IL-4, anti–IL-12, and anti–IFN-γ to generate Th2 cells.
Total RNA was isolated from 2 × 106 naive or activat-
ed T cells, and cDNA was prepared using a cDNA syn-
thesis kit (Amersham Pharmacia Biotech, Piscataway,
New Jersey, USA). cDNA was screened for expression
of murine APRIL (700 bp) employing primers H195
(forward: 5′-AGCCTCATCTCCAGGCCACAT-3′) and
H194 (reverse: 5′-AAACCCCAGGAATGTTCCATGCG-3′)
and murine BLyS (930 bp) employing primers H198
(forward: 5′-ATGGATGAGTCTGCAAAGACCCTG-3′) and
H199 (reverse: 5′-TTACAGCAGTTTTAGG GCACCAAAG-
3′). As a control, cDNA was screened for GAPDH as
described (28). Samples were amplified for 35 cycles
(APRIL and BLyS) or 26 cycles (GAPDH).
Total RNA was isolated from splenocytes and reverse-
transcribed to cDNA. Aliquots from cDNA preparations
were amplified by PCR, generating the complete cDNA
of human APRIL (780 bp) employing primers H14 and
H19, the complete cDNA of murine APRIL (700 bp)
employing primers H195 and H194, or a 445-bp frag-
ment of actin (forward: 5′-ATCAAGATCCTGACCGAGCG-
3′; reverse: 5′-TACTTGCGCTCAGGAGGAGC-3′) (29). The
following conditions were used: 1 cycle at 94°C for 5
minutes, followed by 3 cycles at 94°C for 1 minute, 58°C
for 1 minute, and 72°C for 1 minute, followed by anoth-
er 35 cycles at 94°C for 1 minute, 55°C for 1 minute, and
72°C for 2 minutes. The products were resolved on a 1%
agarose gel. To ensure that the amplified human APRIL
signal was not due to contaminating genomic DNA, the
entire procedure was performed in the absence of reverse
transcriptase. Moreover, cDNA probes were amplified
for Thy1 using primers (forward: 5′-CCATCCAGCAT-
GAGTTCAGCC-3′; reverse: 5′-GCATCCAGGATGTGTTCT-
GA-3′) that amplify a 300-bp fragment of cDNA and a
700-bp fragment of genomic DNA (genomic mouse
DNA was used as a positive control).
Western blot analysis. Cell lysates were prepared in 
NP-40 buffer (1% NP-40, 1 µg/ml leupeptin, 1 µg/ml
aprotinin, 1 mM PMSF in 50 mM Tris, pH 7.4). Fol-
lowing quantification of protein content to ensure
equal loading of the cell samples, lysates were separat-
ed electrophoretically by SDS-PAGE, then transferred
to nitrocellulose. Equal loading and transfer was veri-
fied in each experiment by Ponceau S staining of the
membrane (Sigma-Aldrich). For analysis of mouse sera,
1 µl of each sample was analyzed by Western blot analy-
sis. Immunoblots were probed using 2 µg/ml of affini-
ty-purified anti-APRIL antibody (8) and developed
using the ECL system (Amersham Pharmacia Biotech).
Flow cytometric analysis. Cells were stained with appro-
priate antibodies and analyzed on an EPICS XL flow
cytometer (Beckman Coulter, Fullerton California, USA).
Freshly prepared or cultured lymphocytes were resus-
pended in FACS buffer (1% BSA, 0.05% sodium azide in
PBS). Peripheral blood leukocytes (PBLs) were isolated by
density gradient centrifugation of EDTA-treated mouse
blood over Ficoll-Paque (Amersham Pharmacia Biotech).
Labeled anti-mouse anti-CD4 (L3T4), -CD8 (Ly-2), 
-CD45R/B220 (RA3-6B2), -IgD (11-26c.2a), -IgM 
(R6-60.2), -CD69 (H1.2F3), -CD62L (L-selectin), -CD44
(IM7), -CD45RB (16A), -CD23 (IgE Fc receptor), -CD24
(HSA, 30F1), -CD21, -CD5, -Vβ8 (F23.1), and -Vβ6 
(RR4-7) antibodies, intracellular cytokine staining kit,
and hamster anti–Bcl-2/control hamster Ig kit were pur-
chased from BD PharMingen (Heidelberg, Germany). All
antibodies were used according to the manufacturer’s
specifications. For determination of dead cells, propidi-
um iodide (PI; 2 µg/ml) was added to cell suspensions.
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Antigen-specific antibody production in vivo. For analysis of
T cell–dependent humoral responses, groups of 6- to 
8-week-old APRIL Tg mice and littermates were immu-
nized intraperitoneally with 107 plaque-forming unit
(pfu) per animal of a recombinant form of Western
Reserve strain or a modified version of attenuated
Ankara-strain vaccinia virus (rMVA), which expresses the
entire envelope (env) gene of HIV-1 strain IIIB (MVAenv)
under viral transcriptional control (30). Fourteen days
after inoculation (priming), blood was collected from
the retro-orbital plexus using a heparinized capillary
tube, collected in an Eppendorf tube, and incubated 1–2
hours at room temperature and then overnight at 4°C.
The samples were centrifuged, and serum was obtained
and stored at –80°C. After serum sample collection, mice
received a second intraperitoneal immunization with 107
pfu per animal of MVAenv (boost), and another 14 days
later, mice were bled again. For analysis of TI-2 humoral
responses, mice were immunized intraperitoneally with
100 µl PBS containing 30 µg of 4-hydroxy-nitro-
phenacetyl–conjugated Ficoll (NP-Ficoll) (Biosearch
Technologies). Serum was collected as described above.
Serum Ig and autoantibody analysis. Murine serum Ig’s
were quantitated by standard ELISA techniques using
isotype-specific capture antibodies and specific biotin-
conjugated anti-mouse isotype-specific antibodies (BD
PharMingen); mouse Ig standards recommended by the
manufacturer were used. Dilutions within a linear range
of absorbance were chosen for each experiment. To deter-
mine antibody titers against vaccinia antigens, β-galac-
tosidase, or 4-hydroxy-nitrophenacetyl (NP), the respec-
tive antigen was coated at 1 µg/ml on ELISA plates.
Anti-dsDNA autoantibodies were detected by coating
ELISA plates with 2.5 µg/ml grade I calf thymus DNA
(Sigma-Aldrich). Serum dilutions within the linear range
of absorbance were used for quantification. Absorbance
was measured at 492 nm on a Labsystems Multiskan Plus
plate reader (Thermo Labsystems, Chicago, Illinois, USA).
Cell isolation. T and B cells were purified by negative
selection from lymph nodes or spleens using either B220
or Thy1.2-coupled Dynabeads (Dynal Biotech, Oslo,
Norway), respectively, according to the manufacturer’s
instructions. Cell populations isolated by this method
were at least 95% positive for B220 (B cells) or CD3 
(T cells). In some experiments, CD62L+ cells were sorted
using a Beckman Coulter EPICS ALTRA cell sorter.
Proliferation and survival assays. Cells were plated at 
5 × 104 cells per well and proliferation quantified by 
3H-thymidine uptake (1 µCi/200 µl) during the final 24
hours of culture. T cell proliferation was induced by anti-
CD3 (145-2C11; 0.1 µg/ml) alone or in combination with
anti-CD28 (37.51; 0.3 µg/ml). Survival of cultured cells
was determined by PI uptake. In some experiments, sur-
vival was tested in the absence or presence of Mega-APRIL
(at indicated concentrations; ALEXIS Biochemicals
Corp., Basel, Switzerland). Treatment of Jurkat cells with
recombinant APRIL stimulated proliferation in a dose-
dependent manner, confirming the activity of the re-
agent (not shown). For this, cells were stained with the 
respective markers and analyzed by flow cytometry after
incubation with 2 µg/ml of PI. BCMA-Fc and TACI-Fc
were obtained from ALEXIS Biochemicals Corp.
In vivo T cell response. Staphylococcal enterotoxin B
(SEB) (100 µg in 100 µl PBS; Sigma-Aldrich) was inject-
ed intraperitoneally into mice, and the response of
SEB-reactive T cells was determined by analyzing the
percentage of Vβ8+ CD4+ and CD8+ T cells in blood at
different time points.
Results
APRIL Tg mice. The expression pattern of APRIL on lym-
phoid cells remains ill-defined. Injection of recombinant
APRIL nonetheless results in expansion of the B cell pop-
ulation and T cell activation (18), suggesting that it plays
a role in the immune system. To analyze whether APRIL,
like BLyS (18), is expressed on T cells, we purified TCR
Tg CD4+ T cells from DO11.10 mice. These T cells can be
activated in vitro using an appropriate OVA peptide.
Moreover, these T cells can be directed toward a Th1 or
Th2 phenotype depending on the cytokines present dur-
ing activation (27). Using this model system, we analyzed
APRIL and BLyS expression by RT-PCR. As reported pre-
viously, BLyS expression was upregulated during T cell
activation (Figure 1a) (4). Similarly, APRIL expression
was detected in activated Th1 or Th2 cells, but not in
naive cells (Figure 1a), pointing to a role for this mole-
cule in T cell–dependent immunity.
To study this finding in further detail, we generated a
Tg mouse strain expressing human APRIL under the con-
trol of the lck distal promoter, which directs transgene
expression to mature thymocytes and peripheral T lym-
phocytes (Figure 1b) (26). We confirmed in ELISA assays
that binding of recombinant human APRIL to mouse
TACI and BCMA is comparable to its binding to the cor-
responding human receptors (not shown), which concurs
with a recent report that human APRIL has the same
binding capacities for human and mouse BCMA (31). In
four independent Tg mouse lines, we detected RNA
expression of the transgene (Figure 1c). Only two of these
transgenes displayed detectable levels of the transgene
protein in T cells (Figure 1d), but in no other types of cells
tested (not shown). Moreover, sera from 8-month-old
mice of the Tg 3919 line showed detectable circulating
APRIL levels at concentrations of 1–5 µg/ml (Figure 1e).
Tg mice were born at the expected mendelian ratio, and
histological analysis at 3–12 weeks of age revealed no
gross abnormalities in either of the Tg strains. In addi-
tion, semiquantitative RT-PCR analysis of RNA derived
from APRIL Tg mouse spleens revealed no alterations in
BLyS, TACI, or BCMA RNA expression levels (not
shown). Line 3919 was used for subsequent experiments,
but similar observations were made in line 3923.
T and B cell composition of lymphoid organs. As recombinant
APRIL results in increased spleen weight due to B cell
accumulation (18), we compared the spleens of 12 Tg
mice and their corresponding non-Tg littermates at 6–12
weeks of age. No significant difference was observed in
spleen weight (Figure 2a) or total number of spleen cells
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(Figure 2b), and immunohistological analysis of APRIL
Tg mouse spleen architecture showed no apparent
abnormalities (not shown). Furthermore, no alteration
was observed in spleen weight or total cell number in
older Tg mice tested (age 4–9 months) (not shown). We
next analyzed the B and T cell composition in Tg mouse
secondary lymphoid organs by FACS analysis. No varia-
tion was observed in the percentage of B220+ B cells in
spleen, mesenteric lymph nodes, or Peyer’s patches (Fig-
ure 2c). In contrast, a small increase in the percentage of
B220+ B cells was observed in peripheral lymph nodes in
all Tg mice tested (n = 10) (Figure 2c). The percentages of
both CD4+ and CD8+ T cells were proportionally
decreased (Figure 2d), resulting in a significant decrease
in absolute T cell numbers in Tg mouse peripheral lymph
nodes (Figure 2e). Further analysis of T cells revealed a
striking increase in CD62L– CD4+ and CD8+ T cells in sec-
ondary lymphoid organs, of which only a small percent-
age showed CD44 upregulation (Figure 3). Whereas a
fivefold increase has been observed in CD62L– CD44high
effector T cells in BLyS Tg mice (19), APRIL Tg mice
revealed an accumulation of CD62L– CD44low T cells,
which do not correspond to classically activated T cells.
In agreement, there was no reproducible upregulation of
CD25 or downregulation of CD45RB in the T cells in the
mice analyzed (not shown).
Ectopic APRIL expression prolongs T cell survival in vivo and
in vitro, correlating with increased Bcl-2 levels. Recombinant
APRIL stimulates B and T cell proliferation in vitro (18).
In agreement, purified T cells from APRIL Tg mice
showed increased thymidine incorporation following a
2-day stimulation with anti-CD3 in combination with
anti-CD28, as well as after stimulation with anti-CD3
alone (Figure 4a). The increased in vitro proliferation of
Tg T cells correlated with increased IL-2 production in
CD8+ T cells after in vitro stimulation (Table 1).
To determine whether the increased in vitro T cell pro-
liferation observed can also be detected in vivo, we ana-
lyzed T cell activation using injection of SEB, which inter-
acts predominantly with Vβ8+ T cells (32). Treatment of
mice with SEB leads to systemic activation of all Vβ8+ T
cells. SEB injection leads to an initial increase in the per-
centage of both Vβ8+ CD4+ and Vβ8+ CD8+ T cells. This
initial proliferation is followed by a deletion phase, with
clear decreases in Vβ8+ T cell numbers, which eventually
reach levels lower than those found before SEB treat-
ment. The decrease in Vβ8+ CD4+ cells is due to apopto-
sis of SEB-responsive cells (32, 33); Figure 4b shows a rep-
resentative experiment tracking the percentage of Vβ8+ T
cells in PBLs from APRIL Tg mice and littermates fol-
lowing SEB administration. Both Vβ8+ CD4+ and Vβ8+
CD8+ T cells of APRIL Tg mice show expansion similar to
that of corresponding non-Tg littermates at day 3, indi-
cating that APRIL does not affect the expansion phase of
the T cell response in vivo. In contrast, a significantly
delayed deletion of Vβ8+ CD4+ T cells was observed in
comparison with SEB-reactive cells of littermates; this
was especially evident when the percentage of Vβ8+ CD4+
T cells was compared 7 days after SEB injection. Despite
the clear delay in deletion of CD4+ T cells, no significant
difference was observed in the CD8 response (Table 2).
This lack of effect on the CD8+ T cell response was con-
firmed by analyzing the CD8 response induced after
infection with adenovirus. Using this approach, we
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Figure 1
(a) APRIL expression in activated, but not in naive, T cells. Activated T
cells have increased APRIL mRNA expression levels. DO11.10 spleen
CD4+ T cells were isolated and activated in vitro toward a Th1 or Th2
phenotype. RNA was prepared from naive, Th1, and Th2 cells and used
to analyze the expression of APRIL, BLyS, and GAPDH by RT-PCR.
Generation and characterization of APRIL Tg mice. (b) Schematic dia-
gram of constructs used for peripheral T cell–specific expression of the
human APRIL transgene. (c) mRNA expression of APRIL in T cells of
four different founders. RNA was prepared from purified T cells derived
from spleen and lymph nodes of four Tg mice and analyzed by RT-PCR
for APRIL RNA expression levels. To ensure that the amplified human
APRIL signal was not due to contaminating genomic DNA, cDNA
probes were amplified for Thy1 using primers that amplify a 300-bp
fragment of cDNA and a 700-bp fragment of genomic DNA (genom-
ic mouse DNA was used as control). (d) Protein expression of APRIL
in Tg mouse T cells. Cell lysates were prepared from purified T cells
derived from spleen and lymph nodes of four Tg mice, a control litter-
mate, and a C57BL/6 mouse and analyzed in Western blot using anti-
human APRIL antibodies (8). (e) Secreted APRIL circulates in serum of
APRIL Tg mice. Sera (1 µl) of control and Tg mice were resolved under
nonreducing conditions and immunoblots developed with anti-human
APRIL antibodies. Recombinant (Rec.) APRIL protein (0.1–5 ng)
added to control serum was used as standard.
Downloaded from http://www.jci.org on May 27, 2016.   http://dx.doi.org/10.1172/JCI15034
observed no effect of ectopic APRIL expression in the
CD8+ T cell response to adenovirus (not shown).
To analyze this delayed T cell deletion in further detail,
we tested whether ectopic APRIL-expressing T cells have
an increased survival capacity in vitro. To this end, puri-
fied T cells were cultured for 3 days under various con-
ditions, and survival was determined by measuring PI
uptake. Both CD4+ and CD8+ T cells isolated from Tg
mice showed significantly increased survival compared
with those of littermates (Figure 4, c and d). This differ-
ence became evident only when T cells received subopti-
mal or no stimulus. Increased survival of purified T cells
also became evident by quantification of live and dead
cell gates by forward/side scatter (Table 3). Increased sur-
vival of APRIL Tg T cells was not blocked by BCMA-Fc
or TACI-Fc (Figure 4f). In addition, the increased sur-
vival of nonactivated T cells could not be mimicked by
the addition of recombinant APRIL to T cell cultures
(Figure 4e). Taken together, this suggests that the pres-
ence of APRIL in in vitro cultures is not sufficient to
increase survival of unstimulated T cells, but that Tg T
cells receive this survival signal in vivo.
The augmented survival of B cells observed in BLyS Tg
mice has been associated with increased Bcl-2 expression
levels (19). Bcl-2 expression is especially effective when
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Figure 2
B and T cell homeostasis in APRIL Tg mice. (a)
Unaltered spleen weight in APRIL Tg mice. Spleen
weight of mice was measured at the age of 6–12
weeks (n = 12). (b) Unaltered splenocyte and
peripheral lymph node cell number in APRIL Tg
mice. Splenocyte number was determined in 6- to
12-week-old mice (n = 11). Data represent the
mean ± SD. (c) Evaluation of B cell percentage
(B220+ cells) in spleen, mesenteric lymph nodes
(MLN), Peyer’s patches (PP), and peripheral lymph
nodes (PLN) (n = 10). (d) Percentage of CD4+ and
CD8+ T cell populations in peripheral lymph nodes
of APRIL Tg mice (n = 10; 6–12 weeks old). (e)
Comparison of absolute B and T cell numbers in
peripheral lymph nodes (n = 10). Data are the
mean ± SM. The statistical significance of the data
was determined using ANOVA. P > 0.05 is consid-
ered insignificant, P < 0.05 significant, P < 0.01
very significant, and P < 0.0001 extremely signifi-
cant. Co, control.
Figure 3
Decreased CD62L (L-selectin) expression in splenic T cells is not
accompanied by CD44 upregulation. CD62L versus CD44 expression
is shown gated on CD4 and CD8 populations. Downregulation of
CD62L was seen in T cells of blood and secondary lymphoid organs;
it was already apparent in Tg mouse spleen at 2 weeks of age and was
maintained throughout their lives (not shown).
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cells are deprived of survival factors (34, 35). Moreover,
Bcl-2 has been shown to delay the deletion of SEB-primed
CD4+ T cells (33). We therefore determined Bcl-2 expres-
sion in the APRIL Tg mice and control littermates by
FACS analysis. Ex vivo CD4+ and CD8+ T cells, but not B
cells, displayed a twofold increase in Bcl-2 levels in Tg
mice compared with non-Tg littermates, suggesting that
elevated Bcl-2 levels may be responsible for the prolonged
survival of these cells (Figure 5a).
The increased proliferation, survival, and Bcl-2 expres-
sion may be due to the presence of the relatively large
CD62L– T cell fraction in the Tg animals, which might
represent activated T cells. To exclude this possibility, we
analyzed CD62L+ T cells, which represent the naive T cell
fraction. Like unsorted T cell populations, Tg mouse
CD62L+ T cells showed increased T cell proliferation fol-
lowing anti-CD3/anti-CD28 activation, as well as pro-
longed survival in 3-day cultures (Figure 5, c and d). In
addition, an increase in Bcl-2 expression was detected on
sorted Tg mouse CD62L+ T cells compared with those of
littermates (Figure 5b). This indicates that the survival
and proliferation effects described are not due to the
increase in CD62L– T cells in the Tg mice but are a direct
result of APRIL expression on naive T cells.
APRIL Tg mice display normal B cell development in spleen.
Only mature B cells can recirculate and enter lymphoid
follicles of spleen and lymph nodes. Two spleen B cell
populations, termed type 1 (T1) and type 2 (T2) transi-
tional B cells, were identified as precursors for mature B
cells (36). BLyS preferentially supports the survival of T2
B cells (37). To analyze whether Tg expression of APRIL
had a similar effect on the B cell compartment, we deter-
mined the composition in the spleen. T1 and T2 transi-
tional B cells and marginal zone B cells can be distin-
guished on the basis of IgM, CD21, and CD23 expression
(36). The T1 and T2 transitional B cell subpopulations
are both IgMbright, whereas only T2 cells are CD21bright
CD23+, which also distinguishes them from CD21bright
CD23– marginal zone B cells (36). Triple staining of
spleen B cells from mice Tg for APRIL showed no signif-
icant difference in the percentage of T1, T2, mature, or
marginal B cells (Figure 6). T1 B cells are the precursors
of T2 and mature B cells (36), and T1 B cells are already
detectable in 1-week-old mice, whereas T2 and mature B
cells only become clearly detectable in mice at about 3
weeks of age (36). To exclude that APRIL influences the
kinetics of B cell development, we followed T1 and T2 B
cell formation in mice at various ages; we found that T1
and T2 B cell development is comparable between APRIL
Tg mice and littermates (Figure 6). Notably, B cells in
peripheral lymph nodes of APRIL Tg mice correspond to
mature (IgM+, CD23+, CD21bright, and HSA+) B cells (not
shown). The increased constitutive IgM levels in sera of
APRIL Tg mice suggested an alteration in the B1 cell pop-
ulation (38). B1 cells are characterized by B220 and IgM
expression, but by a lack of CD23 expression; CD5
expression analysis allows a further subdivision into B1a
(CD5+) and B1b (CD5–) subpopulations. We thus deter-
mined the percentages of these cells in the peritoneum.
As shown in Table 4, no significant differences were
found upon analysis of APRIL Tg T cells compared with
those of littermates.
Ectopic APRIL expression moderately alters the T cell–depend-
ent humoral immune response. APRIL stimulates IgM pro-
duction by peripheral blood B cells in vitro (25). We there-
fore compared serum IgM concentrations between APRIL
Tg mice and littermates. IgM serum concentrations of Tg
mice showed an approximately twofold increase, where-
as IgG levels were comparable between Tg mice and lit-
termates (Figure 7, a and b). The twofold difference in
IgM serum levels between Tg mice and littermates per-
sisted in older Tg mice (at age 4–9 months; not shown).
No increase was found in anti-DNA antibodies in Tg
mouse serum (Figure 7c). As ectopic APRIL expression
resulted in increased serum IgM levels, we tested whether
the humoral response is also modulated in APRIL Tg
mice. Mice were challenged with a modified version of
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Table 1
Cytokine production of in vitro activated Tg T cells
IL-2 IFN-γ
CD4 Mean SD P value Mean SD P value
Control 17.3 2.8 0.275 7.9 0.6 0.5307
Tg 25.9 3.4 6.6 3.1
CD8 Mean SD P value Mean SD P value
Control 16.9 1.4 0.0115 27.7 2.6 0.942
Tg 26.5 0.4 26.6 3.1
T cells were cultured for 3 days in the presence of anti-CD3 and anti-CD28 and subsequently analyzed for cytokine production by intracellular FACS staining.
The statistical significance of the data was determined using ANOVA.
Table 2
P values for data in Figure 4b
P values Vβ8+ CD4+ Vβ8+ CD8+
Day 0 0.0913 0.1814
Day 3 0.8303 0.2358
Day 7 0.0135 0.2089
Day 10 0.0121 0.0509
Day 13 0.0134 0.5435
Two-tailed P values comparing the respective percentages of Vβ8+ cells of
Tg and control mice. The statistical significance of the data was determined
using ANOVA.
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Ankara-strain vaccinia virus (MVA) expressing β-galac-
tosidase (gal), a T-dependent antigen (30, 39). Antibody
(IgM and IgG) levels against virus and antigen were meas-
ured 14 days after virus inoculation. Serum samples of
APRIL Tg mice showed increased levels (approximately
twofold) of IgM anti-virus antibodies compared with
serum samples of control mice, while IgG induction was
similar in these mice (Figure 7d). The IgG2a/IgG1 ratio
revealed a Th1 response in both Tg and control mice (not
shown). A second immunization (boost) with MVAgal
virus resulted in a moderate but nonsignificant increase
in IgG in the Tg compared with that of non-Tg littermates
(Figure 7d). Similar data were obtained for the antibody
response to the recombinant antigen (not shown).
We also analyzed the humoral response in APRIL Tg
mice to a wild-type strain of vaccinia virus (a recombi-
nant form of the Western Reserve strain), which
showed a pattern similar to that observed for MVA, i.e.,
a twofold increase in antigen-specific IgM production
within 15 days of immunization (not shown).
Elevated TI-2 humoral response in APRIL Tg mice. Polyva-
lent antigens such as pneumococcal polysaccharides and
Ficoll-conjugated antigens are so-called T cell–independ-
ent type 2 (TI-2) antigens, as they were originally
described to induce T cell–independent immune respons-
es (40). TACI-deficient mice revealed depressed respon-
siveness to TI-2 antigens, manifesting the importance of
that receptor for developing TI-2 responses (22). APRIL
is a known TACI ligand; we therefore evaluated the role
of APRIL in the generation of the TI-2 humoral response.
Immunization of APRIL Tg mice with a model TI-2 anti-
gen, NP-Ficoll, resulted in an increase in IgG response
compared with that of non-Tg littermates (Figure 8a). In
addition, the IgM response was significantly elevated on
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Table 3
Survival of cultured T cells determined by forward scatter and 
side scatter
T cells FSC-low SD P value
Spontaneous death Control 77.6 1.7 0.0009
Tg 35.0 1.2
Anti-CD3 stimulation Control 33.1 3.4 0.0009
Tg 14.0 1.5
Purified T cells were cultured as described for Figure 4, c and d. Forward scat-
ter (FSC) versus side scatter plots were used to determine the percentage of
cells in the FSC-low region, which corresponds to dead cells. The statistical
significance of the data was determined using ANOVA.
Figure 4
Increased proliferation of T cells and survival of T cells from APRIL Tg mice in vitro. (a) Increased proliferation of Tg T cells after 2 days’ culturing
with anti-CD3 alone, or anti-CD3 in combination with anti-CD28. (b) T cell response in APRIL Tg mice in vivo: Delayed deletion of superantigen-
responsive Vβ8+ CD4+ cells in APRIL Tg mice. PBLs were stained for CD4, CD8, and Vβ8 on the days indicated (n = 4). This is one representative
experiment of four performed. ANOVA confirmed that the differences for CD4+ cells at days 7, 10, and 13 are statistically significant (Table 2).
*P < 0.05. The Vβ6+ subpopulation of CD4+ and CD8+ cells was unresponsive at all time points analyzed (not shown). (c and d) Survival of puri-
fied T cells cultured for 3 days alone, with anti-CD3, or with anti-CD3 plus anti-CD28. Cells were stained for CD4 (c) or CD8 (d) and PI as described
in Methods. (e) Purified T cells of C57BL/6 mice were cultured for 2 days without stimulation, alone or in the presence of 5 µg/ml recombinant
APRIL, and PI-stained. (f) Purified CD4+ T cells were cultured for 3 days without stimulation, alone or in the presence of 50 µg/ml of TACI-Fc,
BMCA-Fc, or control Ig. Similar results were obtained for CD8+ T cells. All data in a and c–f are the mean ± SD of triplicate determinations of a
representative experiment of at least three performed. The statistical significance of the data was determined using ANOVA.
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day 8 (Figure 8a). The increased IgG response is particu-
larly evident for IgG1, IgG2a, and IgG2b, as they
remained significantly elevated even into day 14 after
TNP-Ficoll treatment (Figure 8b). IgG3 levels were also
significantly increased at day 8, but we observed a level-
ing at later time points (Figure 8c).
Discussion
The TNF-related ligands APRIL and BLyS and their
cognate receptors BCMA and TACI form a two-lig-
and/two-receptor system implicated in B and T cell
stimulation. APRIL and BLyS are both expressed in
hematopoietic cells, and the functional differences
between APRIL and BlyS within this two-ligand/two-
receptor system have remained largely undefined to
date. Analysis of APRIL Tg mice revealed that APRIL
acts as an in vitro survival factor for T cells and affects
both the humoral and the T cell response in vivo.
T cell survival and proliferation in vitro. T cells derived from
APRIL Tg mice show significantly increased proliferation
as measured by thymidine incorporation, which became
especially evident after activation with anti-CD3/anti-
CD28. This concurs with reports proposing a role for
APRIL as an in vitro T cell stimulator (18, 41); we also
observed that activated T cells divide more rapidly upon
the addition of recombinant APRIL (not shown). The 
elevated production of IL-2 in in vitro activated Tg T cells
probably contributes to their increased proliferation. The
proliferative effect may be mediated by TACI, an APRIL
receptor, whose cell surface expression is upregulated in
activated T cells (42); alternatively, nonactivated T cells
may express a new, yet-undefined APRIL receptor. Sup-
porting the existence of an additional APRIL receptor is
the fact that the Jurkat human leukemia T cell line, which
is highly susceptible to APRIL stimulation, does not con-
tain detectable levels of TACI or BCMA mRNA (42, 43)
(M. Hahne, unpublished data). It has also recently been
reported that fibroblast and epithelial cell lines express a
new, still-unidentified APRIL receptor (44).
In addition to the effect on proliferation, we observed
a highly significant increase in in vitro survival of
ectopically APRIL-expressing T cells under conditions
in which cells are deprived of survival factors and receive
no or suboptimal activation signals. T cell survival coin-
cides with a twofold increase in Bcl-2 levels in these cells.
This would explain the protection observed against
apoptosis induced by growth factor deprivation, as 
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Figure 5
T cells of Tg mice have increased Bcl-2 levels. (a) Increased Bcl-2
expression in CD4+ and CD8+ T cells, but not B cells of APRIL Tg mice.
Ex vivo CD4+ and CD8+ T cells and B220+ B cells from peripheral
lymph nodes were analyzed for Bcl-2 expression as described in Meth-
ods. Staining in cells of control littermates is shown in black (gray
shadow for isotype control, no shadow for Bcl-2 staining); blue shows
isotype control, and red shows Bcl-2 in cells of Tg’s. One representa-
tive staining of four is shown. The average increase in Bcl-2 mean flu-
orescence intensity was 1.5 ± 0.19–fold in Tg CD4 cells (mean ± SD,
n = 4), 1.8 ± 0.4–fold in CD8 cells, and 1.1 ± 0.05–fold in B220+ cells.
(b) Increased Bcl-2 expression in sorted CD62L+ T cells of Tg mice.
Staining in cells of control littermates is shown in black (gray shadow
for isotype control, no shadow for Bcl-2 staining); blue shows isotype
control, and red shows Bcl-2 in cells of Tg’s. One representative stain-
ing of three is shown. (c) T cell proliferation of sorted CD62L+ T cells
after 2 days’ culture with anti-CD3 in combination with anti-CD28.
(d) Survival of sorted CD62L+ T cells cultured for 3 days without stim-
ulation. Data in c and d are the mean ± SD of triplicate determina-
tions of a representative experiment of at least three performed. The
statistical significance of the data was determined using ANOVA.
Figure 6
Ectopic APRIL expression does not influence B cell development in
spleen. Splenocytes were analyzed for their content of T1 (IgMbright
CD21– CD23–), T2 (IgMbright CD21bright CD23+), mature (IgM+
CD21bright CD23+), and marginal zone (IgMbright CD21bright CD23-)
B cells (n = 20).
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Bcl-2 Tg T cells display comparable survival in such
assays (34). Nevertheless, we cannot exclude the impli-
cation of other survival-supporting molecules in APRIL
Tg T cells. In contrast to the effect of APRIL on prolif-
eration, this survival signal cannot be blocked by the
addition of TACI-Fc or BCMA-Fc in vitro. It is therefore
likely that the survival signal is already in place prior to
isolation of the cells. Indeed, we observed that the addi-
tion of recombinant APRIL failed to upregulate Bcl-2
and to protect T cells from dying in vitro (not shown),
suggesting either that APRIL-induced survival is an
indirect effect of in vivo APRIL expression and not
directly mediated by an APRIL receptor on the T cell, or
that an APRIL receptor–mediated survival signal syner-
gizes with other factors present in vivo but not in vitro.
T cell homeostasis in APRIL Tg animals. Despite increased
survival of APRIL Tg T cells in vitro, we observe no con-
spicuous difference in total T cell numbers in these mice.
This correlates with previous observations that Bcl-2 Tg T
cells survive in vitro but do not display perturbed T cell
homeostasis (34). Nevertheless, we also detected increased
in vitro T cell proliferation, which is not mirrored by an
increase in T cell numbers or by a difference in the in vivo
growth kinetics of SEB-activated T cells. Whether this
reflects a difference in signal requirements between in
vitro and in vivo proliferation, similar to that reported for
IL-2–induced T cell proliferation (45), is presently unclear.
Two interesting differences observed in the Tg T cell
pool are the reduction in T cells in peripheral lymph
nodes and an increase in the number of CD62L– T cells,
the latter of which was already apparent at 2 weeks of
age. These events are likely to be connected, as CD62L
participates in lymphocyte recruitment from the blood
into lymph nodes (46). It has been reported that CD62L
expression is not essential for lymphocyte homing to
Peyer’s patches, mesenteric lymph nodes, or spleen but
is required for homing to peripheral lymph nodes (47),
which are the only secondary lymphoid organ that dis-
plays a decreased T cell count in the APRIL Tg mice. It
is thus possible that the decreased percentage of T cells
in peripheral lymph nodes of APRIL Tg mice is the con-
sequence of diminished T cell homing capacity due to
their decreased CD62L expression.
We do not observe complete T cell activation in
APRIL Tg mice, whereas full T cell activation was 
previously reported for mice that had received five con-
secutive injections of recombinant APRIL (18). This is
probably due to the levels attained using these differ-
ent approaches, also reflected by the differential effects
on the B cell compartment. Moreover, injection of
BLyS into mice or ectopic BLyS expression results in an
increased percentage of activated T cells (3, 19). Where-
as ectopic BLyS expression results in an increase in
CD62L–CD44high effector T cells (19), we observed a
marked accumulation of CD62L– CD44low T cells in
APRIL Tg mice. We thus conclude that CD62L– T cell
accumulation in APRIL Tg mice is not linked to
increased Tg T cell activation. Moreover, the increased
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Table 4
No altered percentages of peritoneal B cell populations in APRIL Tg’s
B2 B1a B1b
Co Tg Co Tg Co Tg
Mean 10.5% 13.2% 7% 6.2% 5.3% 7.2%
SD 2.5 3.8 1.8 1.3 1.5 2.0
P value 0.2609 0.4666 0.1570
FACS analysis of peritoneal exudate B cells of 6-week-old mice (n = 5). B220+ cells were classified into B2 (CD23+) and B1 (CD23–) B cells. B1 cells were fur-
ther separated into B1a (CD5+) and B1b (CD5–) cells.
Figure 7
Moderate alteration of serum Ig levels and T cell–dependent humoral
responses in APRIL Tg mice. Comparison of IgM (a) and IgG (b) levels
in APRIL Tg mice (n = 10 in a; n = 6 in b). (c) Anti-DNA autoantibodies
were not elevated in APRIL Tg mice. For comparison, pooled sera of five
MRL-lpr mice were used at the same dilution (1:100) as those of APRIL
Tg mice and littermates, and at a 1:1,600 dilution to obtain a compa-
rable OD value. (d) T cell–dependent humoral response to a modified
version of attenuated Ankara-strain vaccinia virus (rMVA) in APRIL Tg
mice (n = 4). Serum IgM and IgG levels from 8-week-old mice before
immunization (preimmune), 15 days after immunization (priming), and
15 days after second immunization (boost). Statistical significance was
determined using ANOVA.
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in vitro survival and proliferation capacity of Tg T cells
is not linked to the increased CD62L– T cell numbers,
as these features are also detected when sorted CD62L+
Tg T cells are analyzed.
It has been suggested that APRIL is involved in in
vitro T cell proliferation, as anti-APRIL antibodies pre-
vent primary activation in vitro (M. Lenardo, personal
communication), although this does not exclude a role
for BLyS, which was recently shown to provide in vitro
costimulation as well (26). Again, these in vitro obser-
vations remain to be evaluated in vivo, and the receptor
through which these effects are mediated remains
unknown, as no defect in T cell–dependent immunity
in TACI–/– mice has been reported (22).
Ectopic APRIL expression attenuates the deletion kinetics of
SEB-reactive CD4+ T cells. We found that APRIL attenuat-
ed deletion of stimulated CD4+ T cells after SEB treat-
ment. Two independently regulated deletion pathways
have been described that regulate the deletion phase 
of SEB-activated CD4+ T cells (48). One mechanism is 
due to survival factor deprivation, which can be blocked 
by Bcl-2, whereas the other pathway is mediated by 
Fas-induced apoptosis (48). The retarded deletion phase
indeed reflects previous observations in Bcl-2 Tg mice,
confirming the importance of this molecule in the sur-
vival of APRIL Tg T cells. In contrast, deletion of SEB-
reactive CD8+ T cells is regulated by perforin (49), and
this decline is not prevented by constitutive expression
of Bcl-2 (50), even though in vitro survival is observed.
These data are therefore consistent with APRIL-induced
Bcl-2 expression. Similarly, adenovirus-specific CD8+ T
cell responses are not altered in APRIL Tg mice.
Differential APRIL and BLyS function in B cell development.
Tg animals that overexpress BLyS have increased num-
bers of mature B cells, resulting in enlarged spleens,
Peyer’s patches, and lymph nodes (6, 7, 19). We detected
no increase in size or weight of secondary lymphoid
organs in these mice, nor was B cell accumulation
observed in spleen, mesenteric lymph nodes, or Peyer’s
patches, although an increased percentage of mature B
cells was detected in peripheral lymph nodes. This
increase was not reflected in absolute cell numbers, how-
ever, but was due to a decrease in T cells in the lymph
nodes. A possible explanation for this difference may be
that the BLyS expression levels in BLyS Tg mice, in which
the transgene is under the control of an antitrypsin or
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Figure 8
TI-2 humoral response in APRIL Tg mice. Groups (n = 6) of APRIL Tg mice and littermates were immunized with 30 µg NP-Ficoll, a TI-2
antigen, and serum Ig levels were determined by ELISA. (a) IgM and total IgG response to NP-Ficoll. (b) Distribution of IgG1, IgG2a, and
IgG2b isotypes. For comparison, IgG2a levels of preimmune sera are shown; similar values were obtained for IgG1 and IgG2b levels in
preimmune sera. (c) IgG3 response to NP-Ficoll. The statistical significance of the data was determined using ANOVA.
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actin promoter, are much higher than those in APRIL Tg
mice (6, 19). The observation that in vivo administration
of relatively large amounts of recombinant APRIL leads
to B cell accumulation in the spleen, resulting in
increased spleen weight (18), supports this idea. Exposure
to large amounts of APRIL protein may not be physio-
logically relevant, however, and may induce signals in
addition to those that we observed with ectopic APRIL
expression. An alternative and, in our view, more likely
explanation for the difference between APRIL and BLyS
Tg mice is that APRIL and BLyS serve different functions
within the immune system. This is supported by the fact
that the development of most peripheral B cell popula-
tions is severely affected in BLyS-deficient mice, indicat-
ing that APRIL cannot compensate for the missing B cell
survival signals (20, 21). The recent identification of a spe-
cific receptor for BLyS (BAFF-R or BR3) on B cells sup-
ports this conclusion. Disruption of this receptor in
A/WySnJ mice results in a lack of peripheral B cells. This,
combined with the surprising observation that TACI-
deficient mice actually accumulate B cells (22, 23), where-
as deletion of the BCMA gene has no effect on lympho-
cyte homeostasis (20, 24), indicates that the in vivo
survival signals elicited by BLyS are mediated via this
novel receptor. Our results support this conclusion, as
ectopic expression of APRIL, with its potential to bind to
BCMA or TACI but not BR3, does not affect B cell devel-
opment and homeostasis.
APRIL plays a regulatory role in humoral responses.
Although ectopic APRIL expression did not alter either
B2 or B1 B cell numbers, we observed a significant (about
twofold) increase in serum IgM levels in APRIL Tg mice,
while serum IgG levels were unaffected. TACI–/– mice were
shown in one report to have the opposite phenotype, i.e.,
decreased serum IgM but not IgG concentrations (22).
This, combined with the observation that APRIL can pro-
mote IgM secretion in vitro (18), suggests that
APRIL/TACI interactions may have a role in this secre-
tion. Significantly elevated (up to tenfold) serum IgM and
IgG concentrations were also found for BLyS Tg mice (6,
7, 19); furthermore, these mice show greatly increased
autoantibody production, even at the age of 2–4 months
(6, 7, 19). These differences between ectopic APRIL and
BLyS expression can be attributed to the capacity of BLyS
not only to bind to TACI and promote IgM secretion, but
also to bind to BR3 and promote massive expansion of
the B cell compartment. This B cell hyperplasia results in
increased serum Ig concentrations, autoantibody pro-
duction, and B cell responses. Under the conditions of
our study, APRIL does not promote B cell hyperplasia
and thus does not induce these responses.
In addition to an increase in serum IgM levels, we
observed an elevation of T cell–dependent humoral
responses in APRIL Tg mice. This increase in antiviral B
cell responses is only observed for IgM, whereas IgGs are
induced similarly in Tg mice and littermates. It thus
appears that APRIL promotes B cell secretion of IgM but
is incapable of inducing a class switch in a T cell–depend-
ent response, and of promoting IgG secretion.
Unlike the effect on the T cell–dependent humoral
response, APRIL Tg mice had a significantly increased
IgG response to a TI-2 antigen at all time points tested.
An increased IgM response was also seen 7 days after
immunization but equalized later after immunization.
Marginal zone B cells play an important role in
responding to TI-2 antigens (38, 51). Marginal zone
macrophages retain TI-2 antigens and are thus sug-
gested to participate in the generation of TI-2 respons-
es (52). As APRIL is expressed in monocyte/macro-
phages (53), this raises the possibility that endogenous
APRIL secreted by macrophages within the marginal
zone mediates a stimulatory signal to B cells during a
TI-2 humoral response. APRIL Tg mice displayed,
nonetheless, no alterations in marginal zone B cells, as
is also the case for TACI–/– mice (22).
TACI–/– mice are reported to have a block in the TI-2
humoral response (22, 23), indicating a crucial role for
TACI in this response. TACI is expressed on B cells; based
on our observations, we suggest that the APRIL/TACI
interaction participates in TI-2 humoral response as well.
TACI–/– mice fail to develop IgM or IgG responses after
challenge with TI-2 antigens. As ectopic APRIL expres-
sion results in elevated IgM and IgG levels during TI-2
responses, it is likely that TACI receives this stimulatory
signal from APRIL. Whether BLyS contributes to TACI
signaling is not clear. Sequestering BLyS by BR3-Fc injec-
tion is reported to affect TI-2 IgG responses, although
IgM responses were not examined (15); this suggests a
role for BLyS in this response. This role may nonetheless
be exerted through BR3, since A/WySnJ mice, which lack
functional BR3, develop a normal IgM response to the
TI-2 antigen NP-Ficoll, while IgG responses are severely
affected (54). Taken together, the data appear to indicate
that the combined action of BLyS and APRIL through
BR3 and TACI is essential in the maintenance of, and/or
class switching in, the response against TI-2 antigens.
In conclusion, our data provide evidence that APRIL
signals survival of T cells, and that this affects the dele-
tion phase of a CD4+ T cell response in vivo. In addition
to an effect on the T cell response, APRIL mice display
an increase in T cell–dependent IgM responses and 
TI-2 IgM and IgG responses. As BLyS plays a critical role
in B cell responses, BLyS-blocking reagents are present-
ly discussed to treat autoimmunity in humans (55).
Nevertheless, further experiments are needed to eluci-
date whether APRIL and BLyS signals are redundant or
are elicited under distinct circumstances. In contrast,
the effect of APRIL on T cell survival is unique. Whether
this survival signal is also crucial for the T cell response
is a question that must await the generation of APRIL
knockout mice. Our data nonetheless show that APRIL
is involved in both T and B cell responses.
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